Friday's decision by the FDA will give doctors a new tool to help patients who have developed resistance to existing drugs or who are infected with drug-resistant strains of HIV. The drug has been approved for adults who already have been receiving treatment, but more testing is necessary before it is approved for new HIV patients or children, the company said in a statement. These drugs work by blocking the integrase enzyme, which helps HIV replicate by inserting its DNA into new cells. "This property of the virus to integrate is important in establishing the reservoir of virus in the body that has made it extremely difficult to eradicate HIV, even with prolonged treatment. A woman wears an AIDS ribbon at a Cape Town, South Africa, hospital where HIV patients are treated.